Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation
- 1 October 2001
- journal article
- case report
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 28 (7) , 721-724
- https://doi.org/10.1038/sj.bmt.1703222
Abstract
We describe the clinical activity of the ABL kinase inhibitor STI571 in a patient with accelerated phase of chronic myeloid leukemia (CML) relapsing after a second allogeneic BMT and with minimal levels of donor chimerism. STI571 resulted in rapid elimination of leukemic cells with ensuing prolonged severe leukopenia and neutropenia complicated by neutropenic fever and colitis. Subsequent hematopoietic recovery was driven by donor derived cells and was associated with grade 3 graft-versus-host disease (GVHD). STI571 induced sustained hematological and cytogenetic remission combined with controllable GvHD, therapeutic goals not achieved by two preceding allogeneic transplants and repeated donor lymphocyte transfusions (DLT). Bone Marrow Transplantation (2001) 28, 721–724.Keywords
This publication has 12 references indexed in Scilit:
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapseTransplantation and Cellular Therapy, 2001
- Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantExperimental Hematology, 1999
- Donor Leukocyte Transfusions for Treatment of Leukemic Relapse after Bone Marrow TransplantationVox Sanguinis, 1998
- A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantationBone Marrow Transplantation, 1997
- Adoptive immunotherapy with donor lymphocyte transfusionsCurrent Opinion in Oncology, 1997
- Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.Journal of Clinical Oncology, 1997
- Chronic myeloid leukemiaCurrent Opinion in Hematology, 1997
- Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation GroupBlood, 1993